Cargando…

Heart Failure in Patients with Arrhythmogenic Cardiomyopathy

Arrhythmogenic cardiomyopathy (ACM) is a rare inherited cardiomyopathy characterized as fibro-fatty replacement, and a common cause for sudden cardiac death in young athletes. Development of heart failure (HF) has been an under-recognized complication of ACM for a long time. The current clinical man...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shi, Chen, Liang, Duru, Firat, Hu, Shengshou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540844/
https://www.ncbi.nlm.nih.gov/pubmed/34682905
http://dx.doi.org/10.3390/jcm10204782
_version_ 1784589084915662848
author Chen, Shi
Chen, Liang
Duru, Firat
Hu, Shengshou
author_facet Chen, Shi
Chen, Liang
Duru, Firat
Hu, Shengshou
author_sort Chen, Shi
collection PubMed
description Arrhythmogenic cardiomyopathy (ACM) is a rare inherited cardiomyopathy characterized as fibro-fatty replacement, and a common cause for sudden cardiac death in young athletes. Development of heart failure (HF) has been an under-recognized complication of ACM for a long time. The current clinical management guidelines for HF in ACM progression have nowadays been updated. Thus, a comprehensive review for this great achievement in our understanding of HF in ACM is necessary. In this review, we aim to describe the research progress on epidemiology, clinical characteristics, risk stratification and therapeutics of HF in ACM.
format Online
Article
Text
id pubmed-8540844
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85408442021-10-24 Heart Failure in Patients with Arrhythmogenic Cardiomyopathy Chen, Shi Chen, Liang Duru, Firat Hu, Shengshou J Clin Med Review Arrhythmogenic cardiomyopathy (ACM) is a rare inherited cardiomyopathy characterized as fibro-fatty replacement, and a common cause for sudden cardiac death in young athletes. Development of heart failure (HF) has been an under-recognized complication of ACM for a long time. The current clinical management guidelines for HF in ACM progression have nowadays been updated. Thus, a comprehensive review for this great achievement in our understanding of HF in ACM is necessary. In this review, we aim to describe the research progress on epidemiology, clinical characteristics, risk stratification and therapeutics of HF in ACM. MDPI 2021-10-19 /pmc/articles/PMC8540844/ /pubmed/34682905 http://dx.doi.org/10.3390/jcm10204782 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chen, Shi
Chen, Liang
Duru, Firat
Hu, Shengshou
Heart Failure in Patients with Arrhythmogenic Cardiomyopathy
title Heart Failure in Patients with Arrhythmogenic Cardiomyopathy
title_full Heart Failure in Patients with Arrhythmogenic Cardiomyopathy
title_fullStr Heart Failure in Patients with Arrhythmogenic Cardiomyopathy
title_full_unstemmed Heart Failure in Patients with Arrhythmogenic Cardiomyopathy
title_short Heart Failure in Patients with Arrhythmogenic Cardiomyopathy
title_sort heart failure in patients with arrhythmogenic cardiomyopathy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540844/
https://www.ncbi.nlm.nih.gov/pubmed/34682905
http://dx.doi.org/10.3390/jcm10204782
work_keys_str_mv AT chenshi heartfailureinpatientswitharrhythmogeniccardiomyopathy
AT chenliang heartfailureinpatientswitharrhythmogeniccardiomyopathy
AT durufirat heartfailureinpatientswitharrhythmogeniccardiomyopathy
AT hushengshou heartfailureinpatientswitharrhythmogeniccardiomyopathy